NEJM special report authors cite 12 reports from China as further support.

Higher bleeding rates in cancer patients had been found with some other oral anticoagulants.

Italian phase 3 RCT shows most outcomes were numerically but not statistically superior.

Case numbers surge as U.S. tries to "flatten the curve."

Prophylactic use of antimalarials in COVID-19 may limit global supply chloroquine and hydroxychloroquine for other indications.

Short summaries of clinically-relevant COVID-19 stories from the week ending 3 April.

The drug is linked to reduced risk of worsening heart failure or cardiovascular death.

Prognosis with underlying CVD but no myocardial injury is “relatively favorable.”

The course in the infants was mostly mild and brief, with no deaths.

More than a dozen new but incremental recommendations have been added.

Hervé Maisonneuve, Public health physician reminds us of the basic principles of drug development and the dangers that stems from the confiscation of scientific speech by non-scientific journalists and politicians.

Hundreds of clinical trials are currently being investigated in the fight against SARS-CoV-2. The world is working together at an unprecedented rate to find an effective therapy – a summary of the highlights.

Two potential vaccines against COVID-19 have entered phase I clinical trials.

Detailed recommendations for interactions with experimental COVID-19 therapies